Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Income from Continuing Operations: 2010-2024

Historic Income from Continuing Operations for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to -$18.5 million.

  • Ani Pharmaceuticals' Income from Continuing Operations rose 210.07% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 671.57%. This contributed to the annual value of -$18.5 million for FY2024, which is 198.63% down from last year.
  • Ani Pharmaceuticals' Income from Continuing Operations amounted to -$18.5 million in FY2024, which was down 198.63% from $18.8 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Income from Continuing Operations ranged from a high of $18.8 million in FY2023 and a low of -$47.9 million during FY2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$18.5 million (2024), whereas its average is -$15.9 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 1,076.09% in 2020, then soared by 139.21% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$35.8 million in 2020, then declined by 19.16% to -$42.6 million in 2021, then declined by 12.42% to -$47.9 million in 2022, then skyrocketed by 139.21% to $18.8 million in 2023, then plummeted by 198.63% to -$18.5 million in 2024.